1. Home
  2. TGHL vs GDTC Comparison

TGHL vs GDTC Comparison

Compare TGHL & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGHL

The GrowHub Limited Class A Ordinary Shares

N/A

Current Price

$0.31

Market Cap

10.5M

Sector

Technology

ML Signal

N/A

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

N/A

Current Price

$1.03

Market Cap

12.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TGHL
GDTC
Founded
2020
2018
Country
Singapore
Singapore
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TGHL
GDTC
Price
$0.31
$1.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.1K
9.5K
Earning Date
05-18-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.73
52 Week High
$3.80
$3.68

Technical Indicators

Market Signals
Indicator
TGHL
GDTC
Relative Strength Index (RSI) 39.74 45.91
Support Level $0.29 $0.97
Resistance Level $0.51 $1.11
Average True Range (ATR) 0.03 0.05
MACD -0.00 -0.00
Stochastic Oscillator 10.81 45.13

Price Performance

Historical Comparison
TGHL
GDTC

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: